Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $173.25.

A number of research analysts have recently weighed in on the company. Wall Street Zen raised Repligen from a “sell” rating to a “hold” rating in a report on Thursday, May 8th. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Royal Bank of Canada cut their price objective on Repligen from $202.00 to $189.00 and set an “outperform” rating on the stock in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. cut their price objective on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th.

Insider Buying and Selling

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.

Institutional Trading of Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Osterweis Capital Management Inc. grew its holdings in Repligen by 18.0% in the first quarter. Osterweis Capital Management Inc. now owns 72,765 shares of the biotechnology company’s stock valued at $9,259,000 after purchasing an additional 11,080 shares during the period. Strs Ohio acquired a new stake in Repligen in the first quarter valued at approximately $6,069,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Repligen by 7.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,497 shares of the biotechnology company’s stock valued at $32,128,000 after purchasing an additional 17,154 shares during the period. Woodline Partners LP acquired a new stake in Repligen in the first quarter valued at approximately $7,152,000. Finally, United Services Automobile Association acquired a new stake in Repligen in the first quarter valued at approximately $461,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Up 0.9%

Repligen stock opened at $132.87 on Wednesday. The stock has a 50-day moving average of $127.51 and a two-hundred day moving average of $143.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a one year low of $102.97 and a one year high of $182.52. The stock has a market cap of $7.47 billion, a PE ratio of -260.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. During the same period last year, the business posted $0.28 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. On average, research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.